Supplementary

Table S1 Summary of Radiotherapy Dosimetric Parameters (n=20)

Dosimetric Parameters	Median [IQR]
Lung	
Mean Dose (Gy)	17.9 [13.8–18.2]
V5 (%)	47.3 [12.3–22.3]
V20 (%)	19.1 [37.9–57.9]
Heart	
Mean Dose (Gy)	16.0 [11.6–20.4]

Data are presented as median [IQR]. Vx: percentage of the organ volume receiving a dose of at least x Gy; IQR, interquartile range.

https://dx.doi.org/10.21037/tlcr-2026-1-0122

Table S2 Treatment-related adverse events of different treatment stages (n=20)

TRAEs	Induction therapy				Concurrent chemoradiation				Consolidation therapy			
	Grade 1–2	Grade 3	Grade 4	Grade 5	Grade 1–2	Grade 3	Grade 4	Grade 5	Grade 1–2	Grade 3	Grade 4	Grade 5
All causes	19 [95]	9 [45]	6 [30]	0 [0]	16 [80]	9 [45]	1 [5]	0 [0]	18 [90]	2 [10]	2 [10]	1 [5]†
Predominantly chemotherapy-related	19 [95]	9 [45]	6 [30]	0 [0]	12 [60]	5 [25]	1 [5]	0 [0]	12 [60]	1 [5]	1 [5]	0 [0]
Predominantly immunotherapy-related	9 [45]	1 [5]	0 [0]	0 [0]	6 [30]	0 [0]	0 [0]	0 [0]	15 [75]	1 [5]	1 [5]	0 [0]
Predominantly radiotherapy-related	0 [0]	0 [0]	0 [0]	0 [0]	4 [20]	7 [35]	0 [0]	0 [0]	2 [10]	0 [0]	0 [0]	0 [0]
DLT	0 [0]	1 [5]	0 [0]	0 [0]	0 [0]	1 [5]	0 [0]	0 [0]	0 [0]	0 [0]	1 [5]	1 [5]†
SAE	0 [0]	1 [5]	0 [0]	0 [0]	0 [0]	4 [20]	0 [0]	0 [0]	0 [0]	2 [10]	1 [5]	1 [5]†
irAEs	10 [50]	1 [5]	0 [0]	0 [0]	5 [25]	1 [5]	0 [0]	0 [0]	11 [55]	2 [10]	1 [5]	1 [5]†
Leukopenia	12 [60]	4 [20]	2 [10]	0 [0]	4 [20]	4 [20]	0 [0]	0 [0]	1 [5]	0 [0]	0 [0]	0 [0]
Anemia	7 [35]	2 [10]	0 [0]	0 [0]	3 [15]	4 [20]	0 [0]	0 [0]	8 [40]	0 [0]	0 [0]	0 [0]
Neutropenia	5 [25]	4 [20]	6 [30]	0 [0]	1 [5]	4 [20]	0 [0]	0 [0]	2 [10]	0 [0]	0 [0]	0 [0]
Pneumonitis	0 [0]	0 [0]	0 [0]	0 [0]	1 [5]	1 [5]	0 [0]	0 [0]	9 [45]	0 [0]	1 [5]	0 [0]
Fatigue	7 [35]	0 [0]	0 [0]	0 [0]	3 [15]	0 [0]	0 [0]	0 [0]	2 [10]	0 [0]	0 [0]	0 [0]
Anorexia	6 [30]	0 [0]	0 [0]	0 [0]	4 [20]	0 [0]	0 [0]	0 [0]	2 [10]	0 [0]	0 [0]	0 [0]
Radiation esophagitis	0 [0]	0 [0]	0 [0]	0 [0]	5 [25]	3 [15]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Thrombocytopenia	5 [25]	1 [5]	0 [0]	0 [0]	2 [10]	1 [5]	1 [5]	0 [0]	0 [0]	0 [0]	1 [5]	0 [0]
Elevated ALT	6 [30]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	3 [15]	0 [0]	0 [0]	0 [0]
Infusion reaction	5 [25]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	3 [15]	0 [0]	0 [0]	0 [0]
Rash	3 [15]	0 [0]	0 [0]	0 [0]	3 [15]	0 [0]	0 [0]	0 [0]	3 [15]	0 [0]	0 [0]	0 [0]
Elevated AST	4 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [5]	0 [0]	0 [0]	0 [0]
Abdominal pain	3 [15]	1 [5]	0 [0]	0 [0]	1 [5]	0 [0]	0 [0]	0 [0]	2 [10]	1 [5]	0 [0]	0 [0]
Constipation	2 [10]	0 [0]	0 [0]	0 [0]	2 [10]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Radiation dermatitis	0 [0]	0 [0]	0 [0]	0 [0]	3 [15]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Dizziness	1 [5]	0 [0]	0 [0]	0 [0]	1 [5]	0 [0]	0 [0]	0 [0]	1 [5]	0 [0]	0 [0]	0 [0]
Colitis	0 [0]	1 [5]	0 [0]	0 [0]	1 [5]	0 [0]	0 [0]	0 [0]	0 [0]	1 [5]	0 [0]	0 [0]
Weight loss	2 [10]	0 [0]	0 [0]	0 [0]	1 [5]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Hypothyroidism	1 [5]	0 [0]	0 [0]	0 [0]	1 [5]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Pruritus	1 [5]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [5]	0 [0]	0 [0]	0 [0]
Hemoptysis	1 [5]	0 [0]	0 [0]	0 [0]	1 [5]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Chest pain	1 [5]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [5]	0 [0]	0 [0]	0 [0]
Cough	1 [5]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [5]	0 [0]	0 [0]	0 [0]
Nausea/vomiting	1 [5]	0 [0]	0 [0]	0 [0]	1 [5]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Diarrhea	1 [5]	1 [5]	0 [0]	0 [0]	1 [5]	0 [0]	0 [0]	0 [0]	0 [0]	1 [5]	0 [0]	0 [0]
Elevated Cr	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [5]	0 [0]	0 [0]	0 [0]
Hypoproteinemia	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [5]	0 [0]	0 [0]	0 [0]
Arthralgias	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [5]	0 [0]	0 [0]	0 [0]
Xerostomia	0 [0]	0 [0]	0 [0]	0 [0]	1 [5]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Orchialgia	1 [5]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Pneumonia	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [5]†

Data are presented as number [%]. †, the patient succumbed to a probable pneumonia after two cycles of cadonilimab consolidation therapy, with microbiological analysis indicating Klebsiella pneumoniae infection. However, the possibility of treatment-related pneumonitis as an underlying etiology cannot be entirely excluded. ALT, alanine aminotransferase; AST, aspartate aminotransferase; Cr, creatinine; DLT, dose-limiting toxicity; irAEs, immune-related adverse events; SAE, serious adverse event; TRAEs, treatment-related adverse events.

https://dx.doi.org/10.21037/tlcr-2026-1-0122

Table S3 Treatment-related adverse events by treatment phase in patients with PD-L1 tumor cell expression <1% (n=7)

TRAEs	Induction therapy				Concurrent chemoradiation				Consolidation therapy			
	Grade 1-2	Grade 3	Grade 4	Grade 5	Grade 1-2	Grade 3	Grade 4	Grade 5	Grade 1-2	Grade 3	Grade 4	Grade 5
All causes	7 [100]	4 [57.1]	3 [42.9]	0 [0]	6 [85.7]	1 [14.3]	0 [0]	0 [0]	7 [100]	1 [14.3]	1 [14.3]	0 [0]
DLT	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [14.3]	0 [0]
SAE	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	2 [28.6]	0 [0]	0 [0]	0 [0]	1 [14.3]		0 [0]
irAEs	4 [57.1]	0 [0]	0 [0]	0 [0]	1 [14.3]	0 [0]	0 [0]	0 [0]	3 [42.9]	0 [0]	1 [14.3]	0 [0]
Leucopenia	4 [57.1]	2 [28.6]	1 [14.3]	0 [0]	1 [14.3]	1 [14.3]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Anemia	3 [42.9]	1 [14.3]	0 [0]	0 [0]	0 [0]	1 [14.3]	0 [0]	0 [0]	5 [71.4]	0 [0]	0 [0]	0 [0]
Neutropenia	2 [28.6]	1 [14.3]	3 [42.9]	0 [0]	0 [0]	1 [14.3]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Pneumonitis	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	5 [71.4]	0 [0]	1 [14.3]	0 [0]
Fatigue	4 [57.1]	0 [0]	0 [0]	0 [0]	2 [28.6]	0 [0]	0 [0]	0 [0]	1 [14.3]	0 [0]	0 [0]	0 [0]
Anorexia	4 [57.1]	0 [0]	0 [0]	0 [0]	3 [42.9]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Radiation esophagitis	0 [0]	0 [0]	0 [0]	0 [0]	2 [28.6]	1 [14.3]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Thrombocytopenia	3 [42.9]	0 [0]	0 [0]	0 [0]	0 [0]	1 [14.3]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Elevated ALT	3 [42.9]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [14.3]	0 [0]	0 [0]	0 [0]
Infusion reaction	4 [57.1]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Rash	2 [28.6]	0 [0]	0 [0]	0 [0]	1 [14.3]	0 [0]	0 [0]	0 [0]	2 [28.6]	0 [0]	0 [0]	0 [0]
Elevated AST	3 [42.9]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Abdominal pain	2 [28.6]	0 [0]	0 [0]	0 [0]	1 [14.3]	0 [0]	0 [0]	0 [0]	1 [14.3]	1 [14.3]	0 [0]	0 [0]
Constipation	1 [14.3]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Dizziness	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [14.3]	0 [0]	0 [0]	0 [0]
Weight loss	1 [14.3]	0 [0]	0 [0]	0 [0]	1 [14.3]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Hypothyroidism	1 [14.3]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Hemoptysis	1 [14.3]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Chest pain	1 [14.3]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Cough	1 [14.3]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Diarrhea	1 [14.3]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Hypoproteinemia	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [14.3]	0 [0]	0 [0]	0 [0]
Arthralgias	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [14.3]	0 [0]	0 [0]	0 [0]

Data are presented as n [%]. PD-L1, programmed death-ligand 1; DLT, dose-limiting toxicity; irAEs, immune-related adverse events; SAE, serious adverse event; TRAEs, treatment-related adverse events.

https://dx.doi.org/10.21037/tlcr-2026-1-0122

Table S4 Treatment-related adverse events by treatment phase in patients with PD-L1 tumor cell expression 1–49% (n=5)

TRAEs	Induction therapy				Concurrent chemoradiation				Consolidation therapy			
	Grade 1–2	Grade 3	Grade 4	Grade 5	Grade 1–2	Grade 3	Grade 4	Grade 5	Grade 1–2	Grade 3	Grade 4	Grade 5
All causes	5 [100]	4 [80]	1 [20]	0 [0]	4 [80]	2 [40]	0 [0]	0 [0]	4 [80]	0 [0]	0 [0]	0 [0]
DLT	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
SAE	0 [0]	2 [40]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
irAEs	2 [40]	1 [20]	0 [0]	0 [0]	1 [20]	1 [20]	0 [0]	0 [0]	4 [80]	0 [0]	0 [0]	0 [0]
Leukopenia	2 [40]	1 [20]	1 [20]	0 [0]	1 [20]	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Anemia	2 [40]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]
Neutropenia	1 [20]	2 [40]	1 [20]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Pneumonitis	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]
Fatigue	1 [20]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Anorexia	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Radiation esophagitis	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Thrombocytopenia	0 [0]	1 [20]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Elevated ALT	2 [40]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]
Infusion reaction	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]
Rash	1 [20]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]
Elevated AST	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Abdominal pain	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Constipation	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Radiation dermatitis	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Colitis	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Hypothyroidism	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Pruritus	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]
Diarrhea	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Elevated Cr	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]

Data are presented as n [%]. PD-L1, programmed death-ligand 1; DLT, dose-limiting toxicity; irAEs, immune-related adverse events; SAE, serious adverse event; TRAEs, treatment-related adverse events.

https://dx.doi.org/10.21037/tlcr-2026-1-0122

Table S5 Treatment-related adverse events by treatment phase in patients with PD-L1 tumor cell expression ≥50% (n=5)

TRAEs	Induction therapy				Concurrent chemoradiation				Consolidation therapy			
	Grade 1–2	Grade 3	Grade 4	Grade 5	Grade 1–2	Grade 3	Grade 4	Grade 5	Grade 1–2	Grade 3	Grade 4	Grade 5
All causes	5 [100]	1 [20]	1 [20]	0 [0]	5 [100]	1 [20]	0 [0]	0 [0]	4 [80]	1 [20]	0 [0]	1 [20]†
DLT	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]†
SAE	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	1 [20]†
irAEs	4 [80]	0 [0]	0 [0]	0 [0]	3 [60]	0 [0]	0 [0]	0 [0]	4 [80]	2 [40]	0 [0]	1 [20]†
Leukopenia	3 [60]	1 [20]	0 [0]	0 [0]	1 [20]	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Anemia	0 [0]	1 [20]	0 [0]	0 [0]	1 [20]	1 [20]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]
Neutropenia	1 [20]	1 [20]	1 [20]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]
Pneumonitis	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]
Fatigue	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]
Anorexia	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	2 [40]	0 [0]	0 [0]	0 [0]
Radiation esophagitis	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Elevated ALT	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]
Infusion reaction	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]
Rash	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Elevated AST	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]
Abdominal pain	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]
Constipation	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Radiation dermatitis	0 [0]	0 [0]	0 [0]	0 [0]	2 [40]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Dizziness	1 [20]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Colitis	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]
Hemoptysis	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Cough	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]
Nausea/vomiting	1 [20]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Diarrhea	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]
Xerostomia	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Orchialgia	1 [20]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]
Pneumonia	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	0 [0]	1 [20]†

Data are presented as n [%]. PD-L1, programmed death-ligand 1; DLT, dose-limiting toxicity; irAEs, immune-related adverse events; SAE, serious adverse event; TRAEs, treatment-related adverse events.

https://dx.doi.org/10.21037/tlcr-2026-1-0122